Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Cell & Gene Therapy Asia 2019

Yoshikazu Yonemitsu's Biography



Yoshikazu Yonemitsu, Professor, Kyushu University Graduate School of Pharmaceutical Sciences

Professor Yonemitsu graduated in the Faculty of Medicine in 1990, and awarded Ph.D. degree at Kyushu University. He then moved to the National Heart and Lung Institute, Imperial College Collage School of Medicine, London, as a research associate supported by the Wellcome Trust. His expertise in London was the development of highly efficient gene transfer vectors, namely recombinant Sendai virus (rSeV) (Nat Biotechnol, 2000). After going back to Japan, Dr. Yonemitsu started various studies related to translational research, as well as molecular and pathophysiological aspects of atherosclerosis and angiogenesis as an Associate Professor. Then, Professor Yonemitsu got a position at Kyushu University Graduate School of Pharmaceutical Sciences to develop novel gene and cellular therapeutics. His current interest in research is the development of some novel biotherapeutics, including DVC1-0101 as a gene medicine and highly amplified and activated NK-like cell-based cancer adoptive immunotherapy (GAIA-102).

Yoshikazu Yonemitsu Image

A RNA Gene Drug DVC1-0101 Based on Recombinant Sendai Virus Vector to Treat Peripheral Arterial Disease

Tuesday, 12 November 2019 at 11:40

Add to Calendar ▼2019-11-12 11:40:002019-11-12 12:40:00Europe/LondonA RNA Gene Drug DVC1-0101 Based on Recombinant Sendai Virus Vector to Treat Peripheral Arterial DiseaseCell and Gene Therapy Asia 2019 in Kobe, JapanKobe, JapanSELECTBIOenquiries@selectbiosciences.com

A murine paramyxovirus, Sendai virus, was identified and its reconstitution technology has been developed in Japan (recombinant Sendai virus: rSeV). This technology has been a popular method to induce iPS cells, because of its outstanding strong gene expression and safety due to its cytoplasmic transgene expression without genotoxicity. Based on our extensive basic research, combination of rSeV and fibroblast growth factor-2 (FGF-2) (DVC1-0101) exhibited highly effective to rescue the ischemic organs, including limb ischemia; therefore, we moved to clinical studies for patients with peripheral arterial disease (PAD). Now we are conducting a Phase IIb randomized clinical trial to show the efficacy, and patient recruitment would be completed within the end of March 2020. In parallel, Phase I/IIa studies in Australia and China are now ongoing, and upcoming phase III study would be done together with these countries as the international collaboration. In this symposium, the history and future planning of R&D of DVC1-0101 would be presented.


Add to Calendar ▼2019-11-11 00:00:002019-11-12 00:00:00Europe/LondonCell and Gene Therapy Asia 2019Cell and Gene Therapy Asia 2019 in Kobe, JapanKobe, JapanSELECTBIOenquiries@selectbiosciences.com